Navigation Links
CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
Date:5/16/2008

nd CAPHOSOL to other patients at high risk of OM.

Considering that most patients with head and neck cancer experience oral mucositis, any improvements in quality of life for these patients is encouraging, said Dr. Haas. CAPHOSOL is useful for oncology nurses and other healthcare practitioners in helping patients with oral pain and related symptoms of chemoradiation-induced oral mucositis.

Oral Mucositis: A Common and Debilitating Condition

Oral complications including mucositis and salivary gland dysfunction are common and often debilitating side effects of cancer therapy. OM is estimated to affect more than 400,000 cancer patients each year. OM affects approximately 40 percent of cancer patients who receive chemotherapy, more than 70 percent of those undergoing conditioning therapy for bone marrow transplantation, and virtually all patients receiving radiation therapy for head and neck cancer.

Oral mucositis usually manifests itself within seven to 14 days after initiation of therapy. Initial signs and symptoms include redness, swelling and ulceration of the mucosa. Oral mucositis can cause mouth pain, xerostomia (dryness of the mouth or throat), difficulty eating and drinking, as well as difficulty with speech; these effects can significantly impact a patients weight, mood and physical functioning. Severe ulceration may cause breaks in the mucosa, which can then become susceptible to oral opportunistic infections, possibly resulting in bacteremia (the presence of bacteria in the blood), sepsis (the presence of pathogenic microorganisms in the blood) or other potentially fatal complications. The economic impact of mucositis can be significant, as the need for prolonged hospital stays, nutritional therapy and treatments for pain and infection can drive up the costs of therapy.


'/>"/>

Contact: David Avitabile
davitabile@jfkhealth.com
609-514-5117
JFK Communcations
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. More than words: childbirth training change improves safety, cuts unnecessary procedures
2. New surgery improves head and neck cancer treatment
3. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
4. Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report
5. New clinical data shows chromium picolinate improves cognitive function
6. Teamwork improves learning and career success
7. Endobronchial valve significantly improves emphysema
8. Exercise improves thinking, reduces diabetes risk in overweight children
9. Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians
10. Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer
11. Molecular clock could predict risk for developing breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... training video produced by Rafael Ortega, MD, the vice-chair ... Boston Medical Center (BMC) and professor of anesthesiology at ... is featured in this week,s New England Journal ... is the fifth BMC-produced video to appear in the ...
... After 30 years with Chip Supply, Inc., President ... Perrott served in various capacities through the ... tenure, Chip Supply grew into the largest independent die ... global provider of high reliability interconnect solutions, serving the ...
... BUFFALO, NY -- Exposure to air pollution early in life ... may alter her DNA and may be associated with premenopausal ... Buffalo have shown. The findings indicated that higher air ... increase levels of E-cadherin, a protein important to the adhesion ...
Cached Biology News:Pulse oximetry training video by BMC anesthesiologist published in NEJM 2Air pollution exposure affects chances of developing premenopausal breast cancer 2
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation ... executive promotions as well as changes to Martine ... Executive Promotions United Therapeutics announced the ... and Co-Chief Executive Officer and David Zaccardelli , ... In connection with these promotions, Dr. Rothblatt,s title will ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
(Date:12/15/2014)... BEIJING , Dec. 15, 2014  Origin Agritech Limited ... "), a technology-focused supplier of crop seeds in ... results for its fiscal year 2014 ended September 30, 2014, ... The Company will host a teleconference on January 8, ... Beijing time to discuss the results. To participate ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... 18 Martek Biosciences,(Nasdaq: MATK ) announced today ... patented, vegetarian form of DHA omega-3 for brain, eye,and ... vegetarian DHA,Oroweat 9 Grain Bread with life,sDHA from Bimbo ... Pacific Northwest, California, Arizona,and Nevada., "This new launch ...
... Baxter,International Inc. (NYSE: BAX ) announced today ... an additional $2 billion of the company,s,common stock to ... authorization., Baxter has less than $700 million of ... that was authorized in March,2007. Shares will be repurchased ...
... Calif., March 18 TorreyPines Therapeutics,Inc. (Nasdaq: ... Phase II study of,NGX267, a muscarinic agonist in ... syndrome., The company is conducting a randomized, ... to evaluate,the safety, tolerability and efficacy of this ...
Cached Biology Technology:Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4